Search Results - "DOWTY, Martin"

The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans by Dowty, Martin E, Lin, Jinyan, Ryder, Tim F, Wang, Weiwei, Walker, Gregory S, Vaz, Alfin, Chan, Gary L, Krishnaswami, Sriram, Prakash, Chandra

“…Tofacitinib is a novel, oral Janus kinase inhibitor. The objectives of this study were to summarize the pharmacokinetics and metabolism of tofacitinib in…”
Get full text

Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis by Meyer, Debra M, Jesson, Michael I, Li, Xiong, Elrick, Mollisa M, Funckes-Shippy, Christie L, Warner, James D, Gross, Cindy J, Dowty, Martin E, Ramaiah, Shashi K, Hirsch, Jeffrey L, Saabye, Matthew J, Barks, Jennifer L, Kishore, Nandini, Morris, Dale L

“…The Janus kinase (JAK) family of tyrosine kinases includes JAK1, JAK2, JAK3 and TYK2, and is required for signaling through Type I and Type II cytokine…”
Get full text

The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis by Hodge, Jennifer A, Kawabata, Thomas T, Krishnaswami, Sriram, Clark, James D, Telliez, Jean-Baptiste, Dowty, Martin E, Menon, Sujatha, Lamba, Manisha, Zwillich, Samuel

“…Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease characterised by infiltration of immune cells into the affected synovium, release of…”
Get full text

Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites by Wang, Ellen Q., Le, Vu, O'Gorman, Melissa, Tripathy, Sakambari, Dowty, Martin E., Wang, Lisy, Malhotra, Bimal K.

“…Abrocitinib, an oral once‐daily Janus kinase 1 selective inhibitor, is under development for treatment of atopic dermatitis. This phase 1, nonrandomized,…”
Get full text

Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug‐Drug Interactions or in Special Populations: An Example Using Tofacitinib by Tse, Susanna, Dowty, Martin E., Menon, Sujatha, Gupta, Pankaj, Krishnaswami, Sriram

“…Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It is eliminated via…”
Get full text

Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic Model by Saadeddin, Anas, Purohit, Vivek, Huh, Yeamin, Wong, Mei, Maulny, Aurelia, Dowty, Martin E., Sagawa, Kazuko

“…Ritlecitinib, an orally available Janus kinase 3 and tyrosine kinase inhibitor being developed for the treatment of alopecia areata (AA), is highly soluble…”
Get full text

Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers by Guttman-Yassky, Emma, Pavel, Ana B., Diaz, Aisleen, Zhang, Ning, Del Duca, Ester, Estrada, Yeriel, King, Brett, Banerjee, Anindita, Banfield, Christopher, Cox, Lori Ann, Dowty, Martin E., Page, Karen, Vincent, Michael S., Zhang, Weidong, Zhu, Linda, Peeva, Elena

“…Janus kinase (JAK) inhibitors have shown encouraging results in the treatment of alopecia areata (AA), an autoimmune form of hair loss, in small, uncontrolled…”
Get full text

Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1‑((2S,5R)‑5-((7H‑Pyrrolo[2,3‑d]pyrimidin-4-yl)­amino)-2-methylpiperidin-1-yl)­prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans by Thorarensen, Atli, Dowty, Martin E, Banker, Mary Ellen, Juba, Brian, Jussif, Jason, Lin, Tsung, Vincent, Fabien, Czerwinski, Robert M, Casimiro-Garcia, Agustin, Unwalla, Ray, Trujillo, John I, Liang, Sidney, Balbo, Paul, Che, Ye, Gilbert, Adam M, Brown, Matthew F, Hayward, Matthew, Montgomery, Justin, Leung, Louis, Yang, Xin, Soucy, Sarah, Hegen, Martin, Coe, Jotham, Langille, Jonathan, Vajdos, Felix, Chrencik, Jill, Telliez, Jean-Baptiste

“…Significant work has been dedicated to the discovery of JAK kinase inhibitors resulting in several compounds entering clinical development and two FDA approved…”
Get full text

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550) by Ghoreschi, Kamran, Jesson, Michael I, Li, Xiong, Lee, Jamie L, Ghosh, Sarbani, Alsup, Jason W, Warner, James D, Tanaka, Masao, Steward-Tharp, Scott M, Gadina, Massimo, Thomas, Craig J, Minnerly, John C, Storer, Chad E, LaBranche, Timothy P, Radi, Zaher A, Dowty, Martin E, Head, Richard D, Meyer, Debra M, Kishore, Nandini, O'Shea, John J

“…Inhibitors of the JAK family of nonreceptor tyrosine kinases have demonstrated clinical efficacy in rheumatoid arthritis and other inflammatory disorders;…”
Get full text

Correction: Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic Model by Saadeddin, Anas, Purohit, Vivek, Huh, Yeamin, Wong, Mei, Maulny, Aurelia, Dowty, Martin E., Sagawa, Kazuko

Get full text

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF‐06700841) in Healthy Subjects and Patients With Plaque Psoriasis by Banfield, Christopher, Scaramozza, Matthew, Zhang, Weidong, Kieras, Elizabeth, Page, Karen M., Fensome, Andrew, Vincent, Michael, Dowty, Martin E., Goteti, Kosalaram, Winkle, Peter J., Peeva, Elena

“…The safety, tolerability, pharmacokinetics, and pharmacodynamics of PF‐06700841 were assessed in a randomized, double‐blind, placebo‐controlled, single‐ and…”
Get full text

Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis by Dowty, Martin E, Jesson, Michael I, Ghosh, Sarbani, Lee, Jamie, Meyer, Debra M, Krishnaswami, Sriram, Kishore, Nandini

“…A critical piece in the translation of preclinical studies to clinical trials is the determination of dosing regimens that allow maximum therapeutic benefit…”
Get more information

A phase 1 study to investigate the absorption, distribution, metabolism and excretion of brepocitinib in healthy males using a 14 C-microdose approach by Qiu, Ruolun, Sharma, Raman, Wei, Hua, Kirkovsky, Leonid, Zhou, Yifan, Martin, David D A, Banfield, Christopher, Dowty, Martin E

“…Brepocitinib is a tyrosine kinase 2/Janus kinase 1 inhibitor being investigated for the treatment of several autoimmune diseases. This study assessed the…”
Get full text

Integrating Clinical Variability into PBPK Models for Virtual Bioequivalence of Single and Multiple Doses of Tofacitinib Modified‐Release Dosage Form by Purohit, Vivek, Sagawa, Kazuko, Hsu, Hao‐Jui, Kushner, Joseph, Dowty, Martin E., Tse, Susanna, Lin, Jian, Blanchard, Andrew, Mukherjee, Arnab, Le, Vu, Chang, Cheng

“…Tofacitinib is a potent, selective inhibitor of the Janus kinase (JAK) family of kinases with a high degree of selectivity within the human genome's set of…”
Get full text

Identification of N‑{cis-3-[Methyl(7H‑pyrrolo[2,3‑d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases by Vazquez, Michael L, Kaila, Neelu, Strohbach, Joseph W, Trzupek, John D, Brown, Matthew F, Flanagan, Mark E, Mitton-Fry, Mark J, Johnson, Timothy A, TenBrink, Ruth E, Arnold, Eric P, Basak, Arindrajit, Heasley, Steven E, Kwon, Soojin, Langille, Jonathan, Parikh, Mihir D, Griffin, Sarah H, Casavant, Jeffrey M, Duclos, Brian A, Fenwick, Ashley E, Harris, Thomas M, Han, Seungil, Caspers, Nicole, Dowty, Martin E, Yang, Xin, Banker, Mary Ellen, Hegen, Martin, Symanowicz, Peter T, Li, Li, Wang, Lu, Lin, Tsung H, Jussif, Jason, Clark, James D, Telliez, Jean-Baptiste, Robinson, Ralph P, Unwalla, Ray

“…Janus kinases (JAKs) are intracellular tyrosine kinases that mediate the signaling of numerous cytokines and growth factors involved in the regulation of…”
Get full text

The Metabolism and Disposition of Brepocitinib in Humans and Characterization of the Formation Mechanism of an Aminopyridine Metabolite by Dowty, Martin E, Qiu, Ruolun, Dantonio, Alyssa, Niosi, Mark, Doran, Angela, Balesano, Amanda, Wright, Stephen W, Walker, Gregory S, Sharma, Raman

“…Brepocitinib is an oral once-daily Janus kinase 1 and Tyrosine kinase 2 selective inhibitor currently in development for the treatment of several autoimmune…”
Get full text

Effects of Renal Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites by Wang, Ellen Q., Le, Vu, Winton, Jennifer A., Tripathy, Sakambari, Raje, Sangeeta, Wang, Lisy, Dowty, Martin E., Malhotra, Bimal K.

“…Abrocitinib, an oral once‐daily Janus kinase 1 selective inhibitor, is under development for the treatment of atopic dermatitis. This phase 1, nonrandomized,…”
Get full text

Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases by Gerstenberger, Brian S, Ambler, Catherine, Arnold, Eric P, Banker, Mary-Ellen, Brown, Matthew F, Clark, James D, Dermenci, Alpay, Dowty, Martin E, Fensome, Andrew, Fish, Susan, Hayward, Matthew M, Hegen, Martin, Hollingshead, Brett D, Knafels, John D, Lin, David W, Lin, Tsung H, Owen, Dafydd R, Saiah, Eddine, Sharma, Raman, Vajdos, Felix F, Xing, Li, Yang, Xiaojing, Yang, Xin, Wright, Stephen W

“…Tyrosine kinase 2 (TYK2) is a member of the JAK kinase family that regulates signal transduction downstream of receptors for the IL-23/IL-12 pathways and type…”
Get full text

Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition by Telliez, Jean-Baptiste, Dowty, Martin E, Wang, Lu, Jussif, Jason, Lin, Tsung, Li, Li, Moy, Erick, Balbo, Paul, Li, Wei, Zhao, Yajuan, Crouse, Kimberly, Dickinson, Caitlyn, Symanowicz, Peter, Hegen, Martin, Banker, Mary Ellen, Vincent, Fabien, Unwalla, Ray, Liang, Sidney, Gilbert, Adam M, Brown, Matthew F, Hayward, Matthew, Montgomery, Justin, Yang, Xin, Bauman, Jonathan, Trujillo, John I, Casimiro-Garcia, Agustin, Vajdos, Felix F, Leung, Louis, Geoghegan, Kieran F, Quazi, Amira, Xuan, Dejun, Jones, Lyn, Hett, Erik, Wright, Katherine, Clark, James D, Thorarensen, Atli

“…PF-06651600, a newly discovered potent JAK3-selective inhibitor, is highly efficacious at inhibiting γc cytokine signaling, which is dependent on both JAK1 and…”
Get full text

The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Abrocitinib, a Selective Janus Kinase Inhibitor, in Humans by Bauman, Jonathan N, Doran, Angela C, King-Ahmad, Amanda, Sharma, Raman, Walker, Gregory S, Lin, Jian, Lin, Tsung H, Telliez, Jean-Baptiste, Tripathy, Sakambari, Goosen, Theunis C, Banfield, Christopher, Malhotra, Bimal K, Dowty, Martin E

“…Abrocitinib is an oral once-daily Janus kinase 1 selective inhibitor being developed for the treatment of moderate-to-severe atopic dermatitis. This study…”
Get full text